# 9-ING-41 in Patients With Advanced Cancers

> **NCT03678883** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Actuate Therapeutics Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Cancer
- Pancreatic Cancer
- Sarcoma
- Renal Cancer
- Refractory Cancer
- Refractory Neoplasm
- Refractory Non-Hodgkin Lymphoma
- Pancreatic Adenocarcinoma
- Resistant Cancer
- Neoplasm Metastasis
- Neoplasm of Bone
- Neoplasm, Breast
- Neoplasm of Lung
- Neoplasms,Colorectal
- Neoplasms Pancreatic
- Malignant Glioma
- Malignancies
- Malignancies Multiple
- Bone Metastases
- Bone Neoplasm
- Bone Cancer
- Pancreas Cancer
- Pancreatic Neoplasms
- Breast Neoplasms
- Acute T Cell Leukemia Lymphoma

## Interventions

- **DRUG:** 9-ING-41
- **DRUG:** Gemcitabine - 21 day cycle
- **DRUG:** Doxorubicin.
- **DRUG:** Lomustine
- **DRUG:** Carboplatin.
- **DRUG:** Nab paclitaxel.
- **DRUG:** Paclitaxel.
- **DRUG:** Gemcitabine - 28 day cycle
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03678883
- **Lead sponsor:** Actuate Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-04
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03678883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03678883, "9-ING-41 in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03678883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*